<DOC>
	<DOCNO>NCT00405184</DOCNO>
	<brief_summary>This study aim assess safety , tolerability pharmacokinetics Ig NextGen 10 % patient primary immune deficiency currently treat Intragam P. Eligible patient switch 3 4 weekly intravenous Intragam P therapy receive seven cycle Ig NextGen 10 % treatment administer intravenously three- four-weekly interval . Patients monitor study 36 week .</brief_summary>
	<brief_title>Ig NextGen 10 % Patients With Primary Immune Deficiency ( PID )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Clinical diagnosis PID = &gt; 6 month use Intragam P three fourweekly interval = &gt; 6 month history IgG trough level â‰¥ 5 g/L Newly diagnose PID within six month prior Screening Known selective IgA deficiency antibody IgA Immunosuppressive treatment topical and/ inhale steroid and/ low dose oral steroid Proteinlosing enteropathy , kidney disease History malignancy lymphoid cell Any follow laboratory result Screening : Serum Creatinine &gt; 1.5 time upper normal limit ( UNL ) AST ALT concentration &gt; 2.5 time UNL Albumin &lt; 25 g/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>PID</keyword>
	<keyword>IVIg</keyword>
	<keyword>IntragamP</keyword>
</DOC>